The FDA has approved zuranolone as the first oral medication indicated to treat postpartum depression (PPD), affecting 10-20 percent of new mothers. The medication offers a rapid-acting alternative to existing treatments and addresses a condition that can disrupt the maternal-infant bond and have serious consequences for both mother and child development.
SKYLARK Trial Results
The SKYLARK study, published in the American Journal of Psychiatry, randomly assigned 196 patients to receive either zuranolone or placebo for 14 days. New mothers treated with zuranolone experienced a significant 35 percent improvement in depressive symptoms compared to the placebo group, measured by the 17-item Hamilton Depression Rating Scale (HAM-D) score at day 15. They also showed meaningful alleviation in depressive symptoms at days 3, 28, and 45 compared to placebo, with considerably better Clinical Global Impressions severity scores at day 15.
The trial was led by Kristina M. Deligiannidis, MD, professor at the Institute of Behavioral Science at the Feinstein Institutes, who noted that neuroactive steroid research in PPD had been ongoing for nearly 15 years. The medication’s most common side effects included sleepiness, dizziness, and sedation. Notably, there were no reports of loss of consciousness, withdrawal symptoms, or increased suicidal ideation.
Mechanism and Clinical Significance
Zuranolone is a neuroactive steroid and positive allosteric modulator of GABAA receptors that enhances the activity of gamma-aminobutyric acid (GABA), a neurotransmitter regulating mood and anxiety. Unlike traditional antidepressants requiring weeks to take effect, zuranolone has rapid onset of action. The FDA granted the drug Breakthrough Therapy designation based on results from the prior phase 3 ROBIN trial. The drug’s approval provides a much-needed treatment option; currently, zulresso, administered through IV infusion continuously for 60 hours, is the only other drug available to treat PPD.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.psychiatrist.com/news/fast-acting-postpartum-depression-pill-found-safe-effective-in-new-trial/